Primary trastuzumab resistance: new tricks for an old drug.
about
3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cellsTherapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerAntitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsHeparan sulfate mediates trastuzumab effect in breast cancer cellsThe signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR.Investigating the photosensitizer-potential of targeted gallium corrole using multimode optical imaging.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerRapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profilingIntegrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-ActivationA single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cellsNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Lin28A and androgen receptor expression in ER-/Her2+ breast cancer.Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.Lin28 regulates HER2 and promotes malignancy through multiple mechanisms.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.
P2860
Q28485231-23F42271-21B2-40A1-AAE1-CD55ACBE0681Q34268618-0CD1C280-1F71-44F4-8F88-A03658DB1C24Q34348403-0ACD0266-4460-4052-97F1-4F9FD4A2EFA5Q34714574-8EFCBE3A-90D6-4EA0-80AD-9E027A310F7EQ35003529-CE38DFDA-F4F8-45B8-BD1B-79CF27E7BA2EQ35491037-4488A43C-ABE7-484E-8673-98BFEE9655DBQ35652606-D7FD6125-1167-4029-881E-3D2308C13BB5Q36064912-C9B2EA93-6D10-4F61-8470-DF0AD79E7C85Q36388776-4A0F7F1B-E79C-4612-91F7-9108E9FE861BQ36557582-900A474A-42AA-4423-A0EF-90494220C445Q36630127-869A54CB-9533-4FA4-BF76-A912E2DB765FQ36924491-B05EC220-2905-4D4A-B183-62A606B5CB64Q37279627-5D7118DE-45E3-4DBE-AEED-613D879F6B9DQ37381579-0EEC5479-E0AF-492F-B638-E1F30826B4B4Q37671783-823B1632-A4CB-45C0-B8E4-4EE39CBB9D4FQ37699264-E1C0D5C3-6C8A-4915-A155-B1C8D45384A1Q38119307-EE9DE601-4BC0-44B7-B1B5-5ED02710585AQ38788785-CEF1622B-677E-4622-BA22-93441A1A5258Q38861026-20B91D68-D852-49E0-85C5-44ED43E774A4Q39093549-28464464-9075-446B-BA27-C5A86FF75842Q39328419-47E2BA58-AB4D-4D16-919A-8819E2B51DF9Q49544395-8DEF6E90-0C87-4B11-8308-AF14454A3C9A
P2860
Primary trastuzumab resistance: new tricks for an old drug.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Primary trastuzumab resistance: new tricks for an old drug.
@ast
Primary trastuzumab resistance: new tricks for an old drug.
@en
Primary trastuzumab resistance: new tricks for an old drug.
@nl
type
label
Primary trastuzumab resistance: new tricks for an old drug.
@ast
Primary trastuzumab resistance: new tricks for an old drug.
@en
Primary trastuzumab resistance: new tricks for an old drug.
@nl
prefLabel
Primary trastuzumab resistance: new tricks for an old drug.
@ast
Primary trastuzumab resistance: new tricks for an old drug.
@en
Primary trastuzumab resistance: new tricks for an old drug.
@nl
P2860
P1476
Primary trastuzumab resistance: new tricks for an old drug.
@en
P2093
Jason A Wilken
Nita J Maihle
P2860
P356
10.1111/J.1749-6632.2010.05782.X
P407
P577
2010-10-01T00:00:00Z